Yulin Zhao

Dr. Yulin Zhao


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Stem Cells International
Verified
Journal Article
Open access
PWPuyu Wang
Puyu Wang
SXShengshan Xu
Shengshan Xu
QGQian Guo
Qian Guo
YZYulin Zhao
Yulin Zhao
Head and neck squamous cell carcinoma (HNSC) is an aggressive malignancy whose progression is closely associated with dysregulation of programed cell death (PCD) pathways and cancer stem cell (CSC) characteristics. To systematically screen for key pathogenic genes, this study performed single‐cell analysis on the GSE150321 dataset. The identified cell‐specific genes were intersected with PCD‐ and CSC‐related genes, yielding 24 candidate genes for preliminary screening. Further refinement using multiple machine learning (ML) algorithms identified PAK2 as the most central gene among these candidates. Analysis of TCGA and external datasets confirmed that PAK2 is significantly overexpressed in HNSC tissues, demonstrating good diagnostic value and strong association with poor patient prognosis. Functional studies revealed that PAK2 overexpression positively correlates with malignant phenotypes such as metabolic reprograming and tumor metastasis. Notably, PAK2 expression showed a significant negative correlation with antitumor immune status and negatively regulated the infiltration of multiple immune cell types. Spatial transcriptomics and single‐cell sequencing analyses revealed PAK2’s specific expression patterns within the tumor microenvironment, confirming its influence on the activity of immune‐related molecules and immunomodulators. Finally, through Connectivity Map (cMAP) screening and molecular docking, we identified the small molecule compound butein as an effective agent capable of reversing PAK2‐mediated procancer molecular features. Butein exhibits stable binding to the PAK2 protein, suggesting its potential as a targeted therapeutic agent. In summary, through multi‐omics integration analysis, this study first reveals that PAK2 plays a central role in the pathogenesis of HNSC by regulating PCD, tumor stem cell properties, and the immune microenvironment, and provides a candidate drug for its targeted therapy.

20 December 2024 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
QGQian Guo
Qian Guo
DDDong Dong
Dong Dong
QZQiang Zhou
Qiang Zhou
SHShuman Huang
Shuman Huang
XQXinjie Qiao
Xinjie Qiao
YZYulin Zhao
Yulin Zhao
Objective: To investigate the association between cardiovascular health (CVH) and obstructive sleep apnea (OSA) within the U.S. population.Methods: This study enrolled 12,540 participants aged 20 years and older from the 2007–2008 and 2015–2018 cycles of the National Health and Nutrition Examination Surveys (NHANES). Weighted univariate and multivariate logistic regression were utilized to examine the relationship between CVH and OSA symptoms. Life's Essential 8 (LE 8) metrics was employed to evaluate the CVH status of participants. Identification of OSA symptoms was determined based on a sleep questionnaire. They include (1) how often you snore; (2) how often you snort/stop breathing; or (3) how often you feel overly sleepy during day. Individuals who answered that they snore 3 or more per week; snort/stop breathing 3 or more per week and feel overly sleepy during day 16–30 times per month were classified as having OSA symptoms.Results: Significant inverse associations were observed between LE8 scores and symptoms of OSA after adjusting for covariates. The 95% CI was 0.750 (0.630,0.893) for the moderate CVH group and 0.573 (0.454,0.723) for the high CVH group. Subgroup analyses, stratified by age and gender, highlighted a significant interaction between LE8 scores and OSA symptoms with age (P < 0.0001). Participants under 60 years old in the high CVH group exhibited a reduced likelihood OSA symptoms (OR: 0.470; 95% CI: 0.345,0.641). Restricted cubic splines (RCS) in a multivariate regression analysis showed a non-linear relationship between LE8 score and OSA. Our finding demonstrates a substantial decrease in OSA symptom prevalence with increased LE 8 scores.Conclusion: The results demonstrate a strong inverse correlation between LE8 scores and OSA symptoms. Participants with higher LE8 scores showed a reduced likelihood of experiencing OSA symptoms.

29 November 2024 in Medicine
Verified
Journal Article
Open access
QGQian Guo
Qian Guo
DDDong Dong
Dong Dong
XQXinjie Qiao
Xinjie Qiao
SHShuman Huang
Shuman Huang
YZYulin Zhao
Yulin Zhao
Significant progress has been made in the pathogenesis of chronic rhinosinusitis (CRS). However, the relationship between chronic rhinosinusitis with nasal polyps (CRSwNP) and ferroptosis, as well as its underlying molecular mechanism, remains unclear. This study aimed to investigate the correlation between CRSwNP and ferroptosis and identify key gene associated with ferroptosis that could impact the diagnosis and treatment of CRS. To achieve this, gene expression profiles containing CRSwNP and CRSsNP samples were obtained from the GEO database. In addition, from the FerrDb V2 database, we acquired 2 sets of genes that are connected with ferroptosis, giving us a combined number of 260 genes associated with this particular biological process. Differential analysis and weighted gene co-expression network analysis (WGCNA) were performed on nasal tissue samples from GSE36830, leading to the identification of 1 key gene related to ferroptosis and CRS. Using stepwise regression and logistic regression analysis, we constructed a diagnostic model for CRS using ALOX15. The AUC value demonstrates that the model exhibits a strong diagnostic performance. Furthermore, the connection between immune cell infiltration in the samples and hub gene was explored, suggesting the potential significance of the hub gene in the immune response to CRS. Finally, Five drugs targeting a central gene were identified from the DrugBank database, and a few of them have exhibited efficacy in the treatment of CRS or associated ailments. In conclusion, this model holds potential for supporting the diagnosis of CRS patients, while the central gene identified may contribute to a better understanding of CRS development and drug treatment.

15 October 2012 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
DRDaniel R. Radiloff
Daniel R. Radiloff
YZYulin Zhao
Yulin Zhao
ABAlina Boico
Alina Boico
CWChan Wu
Chan Wu
SSSiqing Shan
Siqing Shan
TSThies Schroeder
Thies Schroeder
Decreased physical performance is a well-known consequence of rapid ascent to high altitude. Hypoxic pulmonary vasoconstriction (HPV) potentially limits cardiac output and systemic blood flow, thus preventing successful adaptation to rapid ascent. We hypothesized that pharmacological enhancement of the heart rate with theophylline, combined with reversal of HPV via endothelin blockade, could increase exercise performance at high altitude. Female Sprague-Dawley rats were treated with combinations of 1) theophylline, 2) the endothelin receptor antagonists sitaxsentan/ambrisentan, and/or 3) phosphodiesterase-5 inhibitor sildenafil and exposed to either a simulated high altitude (4,267 m) or 12% oxygen. Exercise capacity, peripheral blood flow, hemodynamics, and pulmonary leak were examined. Combination treatment with theophylline and endothelin blockade, but not with the respective single compounds, significantly prolonged run-to-fatigue time under simulated high altitude. No such efficacy was found when theophylline was combined with sildenafil. Neither theophylline nor sitaxsentan or their combination influenced breathing rates and hemoglobin oxygen saturation. Whereas under hypoxia, theophylline significantly increased muscular blood flow, and sitaxsentan increased tissue oxygenation, the combination improved both parameters but in a reduced manner. Under hypoxia, the combination treatment but not the single compounds significantly enhanced pulmonary arterial pressure compared with controls (13.1 ± 6.3 vs. 11.9 ± 5.2 mmHg), whereas mean arterial pressure remained unaffected. Pulmonary wet-to-dry weight ratios were unaffected by combination treatment. We conclude that concomitant dosing with a cardiac stimulant and endothelin antagonist can partially reverse loss of physical performance capacity under hypobaric hypoxia, independent from improving blood oxygen saturation.

20 June 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
QGQian Guo
Qian Guo
DDDong Dong
Dong Dong
ZDZihan Dang
Zihan Dang
SHShuman Huang
Shuman Huang
XQXinjie Qiao
Xinjie Qiao
YZYulin Zhao
Yulin Zhao
Background: Toripalimab, a monoclonal antibody designed to target PD-1, has recently received approval from the U.S. Food and Drug Administration (FDA) for use as a first-line treatment in adults diagnosed with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC). The purpose of this study is to utilize the FAERS database and bibliometric analysis to examine adverse events associated with toripalimab in real-world settings, thereby enhancing the safety management of clinical medications. Methods: This research implemented a disproportionality analysis to assess the safety of toripalimab by reviewing all adverse event reports from the FAERS database dating back to 2004, wherein toripalimab was recognized as the main suspected medication. Various statistical techniques were applied in the analysis, such as the reporting odds ratio (ROR), proportional reporting ratio (PRR), multi-item gamma Poisson shrinker (MGPS), and Bayesian confidence propagation neural network (BCPNN), to evaluate the adverse events linked to toripalimab. CiteSpace is utilized to search for authors, countries, keywords, and various indicators within research fields, facilitating the identification of research hotspots and future trends. Results: From 2004 to 2024, 441 AEs linked to toripalimab were recorded across 27 SOCs. The top five SOCs were procedural complications, investigations, blood/lymphatic disorders, gastrointestinal disorders, and skin/subcutaneous disorders. At the PT level, the top five AEs by ROR were myelosuppression (n = 192, ROR 687.41), decreased granulocyte count (n = 11, ROR 515.72), immune-mediated hepatic disorder (n = 7, ROR 343.20), immune-mediated myocarditis (n = 3, ROR 214.68), and bicytopenia (n = 3, ROR 117.49). Additionally, 91.62% of AEs occurred within the first 30 days, and immune-related AEs were highlighted in bibliometric analysis. Conclusion: This research provides initial safety information regarding the real-world application of toripalimab, affirming previously acknowledged adverse effects and concurrently uncovering new possible risks. These results could act as important cautionary evidence for healthcare professionals and pharmacists engaged in administering toripalimab for NPC.

30 October 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
QGQian Guo
Qian Guo
YCYicheng Chen
Yicheng Chen
QZQiang Zhou
Qiang Zhou
DDDong Dong
Dong Dong
SHShuman Huang
Shuman Huang
YZYulin Zhao
Yulin Zhao
Laryngeal cancer remains a formidable clinical challenge, with growing evidence that vitamin D 3 acts as a potential therapeutic modulator. However, its precise role is complex, largely due to poor understanding of the mechanisms underlying its variable efficacy. This review synthesizes current knowledge to establish a comprehensive framework for vitamin D 3 ’s dichotomous role in laryngeal carcinogenesis. First, we clarify its two distinct mechanisms of action: (i) directly inhibiting laryngeal cancer cell proliferation and survival via the canonical vitamin D receptor (VDR) axis—triggering G 0 /G 1 cell cycle arrest, inducing apoptosis, and reversing epithelial-mesenchymal transition (EMT); (ii) indirectly exerting anti-tumor effects by reprogramming the tumor immune microenvironment, including enhancing cytotoxicity of CD8 + T and natural killer (NK) cells, promoting dendritic cell maturation, and suppressing key inflammatory pathways such as the COX-2/PGE 2 axis. Subsequently, we propose that the net effect of vitamin D 3 signaling is context-dependent and double-edged, determined mainly by host-intrinsic and viral factors—most notably estrogen receptor α (ERα66) expression. Specifically, vitamin D 3 -related products promote cell growth in ERα66-positive laryngeal cancer cell lines, but suppress growth in ERα66-negative lines, thereby aiding cancer therapy. This integration provides a nuanced paradigm, highlighting the need for biomarker-driven patient stratification to harness vitamin D 3 ’s therapeutic potential in laryngeal cancer.